viewAdmedus Ltd

Admedus implants first ADAPT 3D aortic valve in patient as part of study

The company is conducting the first-in-hiuman surgical aortic valve study.

Admedus Ltd - Admedus implants first ADAPT® 3D aortic vale in patient as part of study
Admedus Ltd is a structural heart company headquartered in Australia

Admedus Ltd (ASX:AHZ) has implanted its first ADAPT single-piece 3D aortic valve in a patient with aortic stenosis.

Professor Bart Meuris at the University Hospitals in Leuven, Belgium conducted the cardiac heart valve surgery.

Fifteen patients will be enrolled in the first-in-human study and followed up for 6 months after receiving implantation of the ADAPT valve.

Results from the study are expected between first quarter of 2021 and third quarter of 2021.

Data will provide “insights to the valve function”

Chief executive officer Wayne Paterson said: “This is a huge milestone for Admedus.

“The data collected on these patients will give us insights to the valve function in the near term proving highly valuable to our TAVR program.

“The preliminary post-operative data initially collected were highly encouraging.

“The trial’s objective is to demonstrate implantation safely.

“It will also provide useful insights into the tissue science and valve design.

“This will help us confirm the clinical benefits relating to haemodynamic function and durability, [while] further building on our strong body of data we have.”

Coronavirus mitigation strategy

Admedus recently confirmed that it will implement a Coronavirus mitigation strategy to limit the risk of an interruption to the continuity of supply and operations.

The company expects the impacts on operations to be minimal but will monitor the situation closely.

In the meantime, the company continues operating to plan and key projects are progressing as scheduled.

Quick facts: Admedus Ltd

Price: 4.2 AUD

Market: ASX
Market Cap: $24.82 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Admedus Ltd named herein, including the promotion by the Company of Admedus Ltd in any Content on the Site, the Company receives from said...



Admedus Ltd proud to unveil its valves publicly for the first time in London

Admedus Ltd's (ASX:AHZ) CEO Wayne Paterson caught up with Proactive's Andrew Scott while in London. The firm recently made what's been described as a transformational move to sell off its CardioCel® and VascuCel® patch business. Paterson says the focus is now firmly on the Adapt...

on 20/11/19

2 min read